Related Experiment Video

Updated: Jun 5, 2026

Mouse In Vivo Placental Targeted CRISPR Manipulation
07:39

Mouse In Vivo Placental Targeted CRISPR Manipulation

Published on: April 14, 2023

Maternal serum insulin-like growth factor-binding protein-1 (IGFBP-1) at 11-13 weeks in pre-eclampsia

Stavros Sifakis1, Ranjit Akolekar, Dimitra Kappou

  • 1Department of Obstetrics and Gynaecology, University Hospital of Heraklion, Crete, Greece.

Prenatal Diagnosis
|January 27, 2011
PubMed

Insights

Maternal serum insulin-like growth factor-binding protein-1 (IGFBP-1) is decreased in early pregnancy for women who develop pre-eclampsia (PE). This finding suggests IGFBP-1 may play a role in PE pathogenesis, independent of placental perfusion.

Area of Science:

  • Reproductive Medicine
  • Maternal-Fetal Medicine
  • Biochemistry

Background:

  • Pre-eclampsia (PE) is a serious pregnancy complication.
  • Early identification of PE risk is crucial for improved maternal and fetal outcomes.
  • Insulin-like growth factor-binding protein-1 (IGFBP-1) is a potential biomarker in pregnancy.

Purpose of the Study:

  • To measure first-trimester maternal serum IGFBP-1 concentrations in pregnancies that later develop PE.
  • To investigate the association between IGFBP-1 levels and uterine artery pulsatility index (PI) in PE.
  • To explore the potential role of IGFBP-1 in the pathogenesis of pre-eclampsia.

Main Methods:

  • Maternal serum IGFBP-1 and uterine artery PI were measured at 11-13 weeks gestation.
  • Data were collected from 60 PE cases (including early-PE) and 120 controls.
  • Levels were expressed as multiples of the median (MoM); regression analysis assessed associations.

Main Results:

  • Median IGFBP-1 MoM was significantly decreased in both early-PE (0.63) and late-PE (0.67) groups.
  • Uterine artery PI MoM was increased in early-PE (1.31) and late-PE (1.19) groups.
  • No significant association was found between IGFBP-1 MoM and uterine artery PI MoM in PE pregnancies (p = 0.210).

Conclusions:

  • First-trimester serum IGFBP-1 is reduced in pregnancies that develop PE.
  • This suggests IGFBP-1 may be involved in PE development through mechanisms not directly related to impaired placental perfusion.
  • IGFBP-1 warrants further investigation as a potential early biomarker for pre-eclampsia.
Abstract

More Related Videos

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas05:31

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Published on: January 26, 2024

Related Concept Videos

Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...